Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00093483 · ClinicalTrials.gov registry record · Phase 1

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

A Phase 1 study of Leukemia, sponsored by Roswell Park Cancer Institute.

Completed
Registry status
Phase 1
Development phase
61
Enrollment target
1
Study location

NCT00093483: Completed Phase 1 study of Leukemia, sponsored by Roswell Park Cancer Institute.

NCT00093483 is a Phase 1 study of Leukemia that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 61 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00093483, a Phase 1 study of Leukemia, has completed, sponsored by Roswell Park Cancer Institute.

COMPLETED
Registry status
Phase 1
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of arsenic trioxide when given together with cytarabine and idarubicin in treating patients with acute myeloid leukemia.

Conditions Studied

Leukemia

Interventions

  • BIOLOGICAL filgrastim
  • DRUG cytarabine
  • DRUG idarubicin
  • DRUG arsenic trioxide

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2002-04
Est. Completion 2009-12
Phase Phase 1
Roswell Park Cancer Institute

365 total trials

What the finished NCT00093483 record still lists

NCT00093483 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 4 interventions - of which filgrastim is the first listed.

NCT00093483 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00093483 about?

NCT00093483 is a clinical study titled "Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, cytarabine, and idarubicin, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase I trial is studying the side effects and b...

What is the current status of trial NCT00093483?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2002-04. Estimated completion is 2009-12.

What conditions does trial NCT00093483 study?

This clinical trial studies the following conditions: Leukemia.

What interventions are being tested in trial NCT00093483?

The interventions under investigation include: filgrastim (BIOLOGICAL), cytarabine (DRUG), idarubicin (DRUG), arsenic trioxide (DRUG).

Who is sponsoring clinical trial NCT00093483?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00093483 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00093483's enrollment target sits among peer trials

61 97th of 233 higher than 136 of 233 other Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00093483, the US trial registry maintained by the National Library of Medicine. NCT00093483 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.